Antithrombotic therapy in high-risk patients after percutaneous coronary intervention; study design, cohort profile and incidence of adverse events

R.H. Olie*, P.E.J. van der Meijden, M.J.A. Vries, L. Veenstra, A.W.J. van't Hof, J.M. ten Berg, Y.M.C. Henskens, H. ten Cate

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Web of Science)
Original languageEnglish
Pages (from-to)525-535
Number of pages11
JournalNetherlands Heart Journal
Volume29
Issue number10
Early online date1 Sep 2021
DOIs
Publication statusPublished - Oct 2021

Keywords

  • Anticoagulation
  • Antiplatelet therapy
  • Antithrombotic treatment
  • Percutaneous coronary intervention
  • Coronary artery disease
  • Bleeding
  • DUAL ANTIPLATELET THERAPY
  • TREATMENT PLATELET REACTIVITY
  • ARTERY-DISEASE
  • BLEEDING SCORE
  • CLOPIDOGREL
  • DEFINITION
  • VALIDATION
  • PRASUGREL
  • CONSENSUS
  • IMPLANTATION

Cite this